S M Moghimi

Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.

S M Moghimi, A C Hunter, T L Andresen, 2012, Annual review of pharmacology and toxicology.

Complement activation turnover on surfaces of nanoparticles.

S M Moghimi, D. Simberg, S. Moghimi, 2017, Nano today.

Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth.

S M Moghimi, S. Moghimi, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption.

Dipak K. Sarker, S M Moghimi, A C Hunter, 2006, Journal of nanoscience and nanotechnology.

Long-circulating and target-specific nanoparticles: theory to practice.

S M Moghimi, A C Hunter, S. Moghimi, 2001, Pharmacological reviews.

Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.

J Szebeni, S M Moghimi, S. Moghimi, 2003, Progress in lipid research.

Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.

J Szebeni, S M Moghimi, A C Hunter, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.

S M Moghimi, A C Hunter, S. Moghimi, 2000, Trends in biotechnology.

Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.

S M Moghimi, T L Andresen, T. Andresen, 2009, Molecular immunology.

Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers.

S M Moghimi, S. Moghimi, 2002, Biochimica et biophysica acta.